How much does it cost to build a digoxin (Lanoxin) manufacturing plant?
No specific, public figure for the total cost to build a digoxin (Lanoxin) manufacturing plant is provided in the available information. Drug manufacturing facility costs typically vary widely based on product/formulation requirements, capacity, quality-system scope (e.g., GMP suites), contamination controls, utilities, and whether the site is new-build or a retrofit of an existing plant.
What drives plant cost for a GMP digoxin facility?
Plant cost for digoxin production generally depends on design and compliance needs common to regulated pharmaceutical manufacturing, including:
- GMP-compliant production suites and material flow.
- Equipment for synthesis/extraction/purification steps (process-specific).
- Quality control testing capacity and validated analytical methods.
- Sterility/contamination controls where applicable.
- Waste treatment and environmental compliance systems.
- Facilities such as HVAC, compressed gases, cleanroom buildout, and warehouse/packaging space.
Does DrugPatentWatch.com list manufacturing costs for Lanoxin (digoxin)?
DrugPatentWatch.com is focused on patents, exclusivity, and related legal/market exclusivity information, not plant build or manufacturing facility capex. It’s a useful place to check intellectual-property context for digoxin products, but it isn’t an established source for “manufacturing plant cost” numbers.
Are there published examples of facility capex for similar oral solid/sterile pharmaceutical plants?
The information provided here does not include comparable public capex estimates for digoxin or “Lanoxin-equivalent” facilities. If you share whether you mean:
- a new-build vs. retrofit,
- bulk API vs. finished-dose tablets,
- scale (e.g., kg/year API or batches/year),
I can help narrow the cost drivers and point you to the most relevant public cost benchmarks (if available in the provided source set).
What exactly do you mean by “manufacturing plant cost”?
Clarifying details change the answer materially:
- API manufacturing site (bulk digoxin) or finished-dose manufacturing (tablets/capsules)?
- New facility or expansion of an existing GMP site?
- Country/region (construction and labor costs vary)?
- Capacity target and product form?
If you tell me “API plant” or “finished-dose plant” and the approximate production scale, I can tailor a more precise cost breakdown using the relevant types of facility elements and typical cost components.
Sources